Agila Specialties Pharma Corporation, Canada, which is part of the injectable drug division of Strides Arcolab, a globally renowned generic drug manufacturer, has formed a joint venture (JV) with Jamp Pharma, a Canadian generic drug company, to introduce a variety of quality injectable generic drug in Canada.
This sales and marketing joint venture will operate under the name Agila-jamp Canada Inc in which Agila will hold 70% stake and the remaining 30% by Jamp Pharma. The JV will be headquartered in Boucherville, Quebec.
Agila-jamp will be launching around 40 products in the next 2 years. Many of these products have already been approved by Health Canada and will be immediately launched through local hospital and pharmacists. The existing sales force at Jamp Pharma will be responsible to introduce the entire Agila-Jamp product portfolio.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
